Your browser doesn't support javascript.
loading
Global disparities in the treatment of idiopathic inflammatory myopathies: results from an international online survey study.
Ziade, Nelly; Aoude, Marc; Hmamouchi, Ihsane; R, Naveen; Lilleker, James B; Sen, Parikshit; Joshi, Mrudula; Agarwal, Vishwesh; Kardes, Sinan; Day, Jessica; Makol, Ashima; Milchert, Marcin; Gheita, Tamer; Salim, Babur; Velikova, Tsvetelina; Edgar Gracia-Ramos, Abraham; Parodis, Ioannis; Nikiphorou, Elena; Chatterjee, Tulika; Tan, Ai Lyn; Saavedra, Miguel A; Shinjo, Samuel Katsuyuki; Knitza, Johannes; Kuwana, Masataka; Nune, Arvind; Cavagna, Lorenzo; Distler, Oliver; Chinoy, Hector; Agarwal, Vikas; Aggarwal, Rohit; Gupta, Latika.
Afiliação
  • Ziade N; Rheumatology Department, Saint-Joseph University, Beirut, Lebanon.
  • Aoude M; Rheumatology Department, Hotel-Dieu de France Hospital, Beirut, Lebanon.
  • Hmamouchi I; Rheumatology Department, Saint-Joseph University, Beirut, Lebanon.
  • R N; Rheumatology Department, Hotel-Dieu de France Hospital, Beirut, Lebanon.
  • Lilleker JB; Laboratory of Clinical Research and Epidemiology, Faculty of Medicine, Mohammed V University, Rabat, Morocco.
  • Sen P; Department of Medicine, Health Sciences College, International University of Rabat (UIR), Rabat, Morocco.
  • Joshi M; Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
  • Agarwal V; Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
  • Kardes S; Neurology, Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, UK.
  • Day J; Maulana Azad Medical College, New Delhi, Delhi, India.
  • Makol A; Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India.
  • Milchert M; Mahatma Gandhi Mission Medical College, Navi Mumbai, Maharashtra, India.
  • Gheita T; Department of Medical Ecology and Hydroclimatology, Istanbul Faculty of Medicine, Istanbul University, Capa-Fatih, Istanbul, Turkey.
  • Salim B; Department of Rheumatology, Royal Melbourne Hospital, Parkville, VIC, Australia.
  • Velikova T; Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • Edgar Gracia-Ramos A; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.
  • Parodis I; Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.
  • Nikiphorou E; Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University, Szczecin, Poland.
  • Chatterjee T; Rheumatology Department, Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt.
  • Tan AL; Rheumatology Department, Fauji Foundation Hospital, Rawalpindi, Pakistan.
  • Saavedra MA; Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria.
  • Shinjo SK; Department of Internal Medicine, General Hospital, National Medical Center, 'La Raza', Instituto Mexicano del Seguro Social, Mexico City, Mexico.
  • Knitza J; Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Kuwana M; Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Nune A; Centre for Rheumatic Diseases, King's College London, London, UK.
  • Cavagna L; Rheumatology Department, King's College Hospital, London, UK.
  • Distler O; Center for Outcomes Research, Department of Internal Medicine, University of Illinois College of Medicine, Peoria, IL, USA.
  • Chinoy H; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK.
  • Agarwal V; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
  • Aggarwal R; Departamento de Reumatología, Hospital de Especialidades Dr Antonio Fraga Mouret, IMSS, Centro Médico Nacional La Raza, Mexico City, Mexico.
  • Gupta L; Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Rheumatology (Oxford) ; 63(3): 657-664, 2024 Mar 01.
Article em En | MEDLINE | ID: mdl-37228012
ABSTRACT

OBJECTIVES:

We aimed to explore current practice and interregional differences in the treatment of idiopathic inflammatory myopathies (IIMs). We triangulated these observations considering countries' gross national income (GNI), disease subtypes, and symptoms using patient-reported information.

METHODS:

A cross-sectional ancillary analysis of the 'COVID-19 vaccination in auto-immune disease' (COVAD) e-survey containing demographic characteristics, IIM subtypes (DM, PM, IBM, anti-synthetase syndrome [ASSD], immune-mediated necrotizing myopathy [IMNM], overlap myopathies [OM]), current symptoms (surrogate for organ involvement) and treatments (corticosteroids [CS], immunomodulators [IM], i.e. antimalarials, immunosuppressants [IS], IVIG, biologic treatments and targeted-synthetic small molecules). Treatments were presented descriptively according to continents, GNI, IIM and organ involvement, and associated factors were analysed using multivariable binary logistic regressions.

RESULTS:

Of 18 851 respondents from 94 countries, 1418 with IIM were analysed (age 61 years, 62.5% females). DM (32.4%), IBM (24.5%) and OM (15.8%) were the most common subtypes. Treatment categories included IS (49.4%), CS (38.5%), IM (13.8%) and IVIG (9.4%). Notably, treatments varied across regions, GNI categories (IS mostly used in higher-middle income, IM in lower-middle income, IVIG and biologics largely limited to high-income countries), IIM subtypes (IS and CS associated with ASSD, IM with OM and DM, IVIG with IMNM, and biologic treatments with OM and ASSD) and disease manifestations (IS and CS with dyspnoea). Most inter-regional treatment disparities persisted after multivariable analysis.

CONCLUSION:

We identified marked regional treatment disparities in a global cohort of IIM. These observations highlight the need for international consensus-driven management guidelines considering patient-centred care and available resources.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Miosite Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Líbano

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Miosite Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Líbano